The biotech industry includes bio-pharma, bio-services, bio-agri, bio-industrials and bioinformatics. Biopharma is a rapidly growing segment that accounts for a dominant share in this sector. Advancements in biotechnology have enabled researchers to evaluate and identify target biomarkers/cell receptors to develop targeted and personalized therapies. Scientific research and technological advancements have resulted in the emergence of various personalized medicines that are undergoing research. According to research conducted by the Personalized Medicine Coalition, 42% of all compounds and 73% of oncology compounds in the pipeline possess the potential to be personalized medicine. Moreover, according to this study, it is expected that companies will increase their investment in R&D of personalized medicines by 1/3rd over the following five years. The study found that over 20% of drugs approved in 2014 were personalized medicines.
The biotechnology sector has witnessed some disruptive innovations such as gene and cell therapies, immunotherapy, and antibody drug conjugates. Advancement in stem cell therapy is resulting in effective treatment therapies for chronic conditions, organ growth and repair and disease prevention.
Biotech products have extensive application in oncology and autoimmune disease treatment. However, the cost of these drugs is high owing to extensive research and trials that need to be carried out for the same. Therefore, there is constant pressure to reduce price and increase accessibility, especially in emerging economies. In the U.S., companies are facing reimbursement issues with respect to biopharmaceutical products. Besides, there are regulatory and scientific challenges faced by the sector. Scientific research for new molecules and targeted therapies is capital intensive and challenging owing to growing concern for safety of the drug.
Also, there is lack of awareness about personalized medicine among most healthcare providers, which may hamper its adoption. Clinical adoption of biotechnology products is essential for its success. However, it significant scientific evidence and backing is required to ensure its safety.
“Translating genomic discoveries into personalized medicines entails overcoming substantial scientific, regulatory, and economic challenges, including identifying validated biomarkers, as well as developing personalized therapeutics and clinically relevant diagnostic tests.”
The biopharmaceutical sector offers vast lucrative growth opportunities. High efficacy and safety of biopharmaceutical products has led to a growth in their demand, Furthermore, consumers are willing to pay high prices for biopharmaceutical products compared to other conventional products. Biopharmaceutical brands have set new standards for blockbuster drugs by recording an annual average sale of over US$ 2bn. Drugs such as Humira have generated sales revenue of over US$ 10bn.
Governments in emerging economies are endorsing biosimilars as cost-effective alternatives to biotech products, which is expected to create significant growth opportunities for manufacturers of generic drugs. Therefore, cost-effectiveness and high quality are prime parameters that need to be considered while developing biosimilars. Recent and upcoming biologic patent expirations include the following:
Companies such as Teva Pharmaceuticals, Hospira, Sandoz, and Amgen are focusing on development of biosimilars and vaccines as preventive measures in addition to treatment. For instance, in 2015, Zarxio TM became the first biosimilar to be approved in the U.S. market. The EMA approved Mosquirix, a malaria vaccine, in the same year. Extensive research is currently underway to develop a dengue vaccine, which could be another breakthrough pharmaceutical product in the near future.
The increasing research in the biotechnology sector is expected to result in higher number of biopharmaceutical products seeking FDA approvals. Biopharmaceuticals are positioned to be promising treatment solutions that would improve patient outcomes and help with reduction of the cost of drug development.
The immune system releases certain inflammatory chemicals to fight against microbial infections like dysentery, hepatitis and others however, when these chemicals start acting against body’s own tissues and organs it leads to a condition known as sepsis. T... View more
Flow Cytometry Market – It’s not just for immunologist anymore The requisite for disease diagnosis and advancements in technology of flow cytometry, in turn are expected to fuel growth of the fl... View more
Biochips Market - Insights Biochips are miniaturized laboratories, which can perform simultaneous biochemical reactions. On the basis of functionality, biochips are classified as DNA chips, protein chips, lab... View more
Influenza is an infection caused by influenza virus and is commonly known as flu. Vaccination for influenza aids in prevention of flu. This vaccine is recommended for children aged 6 months and older. Moreover, according to the World Health Organization (WHO), 2017, i... View more
Cell-free Protein Expression Market – Insights Cell-free protein expression, also known as in vitro translation, in vitro protein expression, cell-free translation, or cell-free protein synthesis), is the p... View more
Global Pharmacogenomics Market - Insights Pharmacogenomics deals with the influence of genetic variation on drug response in patients by correlating gene expression changes and Single-Nucleotide Polymorphisms... View more
Biologics drugs can be defined as molecules derived from living cells such as microorganism, or plant, or animal cells and used for the treatment, diagnosis, or prevention of various diseases. Biologic therapeutics has proven to be a highly effective treatment for var... View more
Industrial Microbiology Market – Insights Industrial microbiology is a branch of applied microbiology in which microorganisms are used in industrial processes. It finds application ... View more
Viral Vector and Plasmid DNA Manufacturing Market-Market Insights Viral vectors are used as carriers to transfer the genetic material into other living organisms. The viral vector production can be done in tw... View more
Platelet-rich plasma (PRP), also called platelet enriched plasma or platelet gel, is a blood plasma product, which contains elevated level of platelets and growth factors (at least four to ten times) than normal blood concentration. An increased blood plasma con... View more
Recombinant DNA Technology Market – Power of Genetic Engineering in Improving Lives Recombinant DNA (rDNA) technology is a novel technique which have led to the advances in a number of different fields ... View more
Biosimilar products are suspected to continue to have a significant impact on the pharmaceutical industry. Many regulatory bodies have established clinical guidelines to support the development of biosimilars, laying down the requirements for demonstrating comparable ... View more
Cell Lysis Market – Insights Cell lysis is the first step of protein extraction, which is further used for different application such as enzyme engineering and protein labelling. Furthermore, cell lysis... View more
3D cell culture is an artificially created environment. 3D cell culture is a culture environment that allows biological cells to interact with their surroundings in all three dimensions. Cells grown in 3D cell culture exhibit similar properties of cells found in livin... View more
Forensic Technologies and Services Market – Insights Advanced technologies in forensics science has been the substantial importance in recent years. Few examples of such advancements include enhanced ... View more
Bone Marrow Transplant Market – Insights Bone marrow is a soft vascular tissue present in the interior of long bones. It consists of two types of stem cells: hematopoietic and mesenchymal stem cells. Bone mar... View more
Personalized Cell Therapy Market - Insights Individualized treatment for various diseases such as cancer and autoimmune diseases by injecting living cells into a patient’s body is known as personalized cell th... View more
B-Cell Maturation Antigen (BCMA) Targeted Therapy – An innovative therapy for multiple myeloma Multiple myeloma (MM) refers to a clonal plasma cell malignant neoplasm that is observed in the soft, spong... View more